Boundless Bio amends Serapha merger deal on RSUs, warrants and share vote terms
Boundless Bio signed Amendment No. 1 to its merger agreement with Serapha Bio on August 28, 2026, changing how Serapha equity awards, certain merger consideration and a share authorization vote are handled. The filing does not state a deal value, and the amendment otherwise leaves the original June 22, 2026 terms unchanged, so shareholders should watch the Form S-4 and proxy statement for the full effect.
Key points
- Amendment No. 1 dated August 28, 2026; original Merger Agreement signed June 22, 2026 with Serapha Bio, Inc.
- Serapha restricted stock units, vested or unvested, convert into Boundless Bio restricted stock units adjusted by the Exchange Ratio
- Pre-funded warrants with a $0.00001 exercise price can be issued as merger consideration where share ownership limits would be exceeded
- Authorized share increase now requires a majority of shares properly cast, rather than a majority of shares outstanding
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.